OneCyte x Kemp Proteins: Fixing the Most Broken Step in Biologics Development

OneCyte x Kemp Proteins: Fixing the Most Broken Step in Biologics Development

By, Admin 7 April 2026

Most biologics don’t fail in clinical trials. They fail before they even get there. The bottleneck? Cell line development. Now, OneCyte and Kemp Proteins are teaming up to fix it.

The Core Problem: Slow, Unpredictable, Expensive

Let’s call it what it is. Cell line development today is:

  • Slow (months to years)
  • Inefficient (low yields)
  • Risky (high failure rates)

And it gets worse with:

  • Complex biologics
  • Non-antibody formats
  • Emerging therapeutic modalities

Result? Delayed timelines. Higher costs. Lost opportunities.

The Partnership in One Line

Design better molecules upfront → validate them faster → scale the best performers That’s the play.

What Each Company Brings?

This is a classic design + execution stack.

1. Kemp Proteins: Predict Before You Build

Kemp Proteins brings its ML-driven platform:

  • PROTiQ (in silico design engine)

What it does:

  • Evaluates amino acid sequences
  • Identifies developability risks
  • Flags structural liabilities
  • Optimizes candidates before lab work

Translation: Fewer bad molecules enter the pipeline.

2. OneCyte: Find the Best Cell Faster

OneCyte brings:

  • High-throughput single-cell analysis platform

Capabilities:

  • Rapid clone screening
  • High-sensitivity detection
  • Fast identification of elite producer cells

Translation: The best-performing cells are found quickly.

The Real Innovation: Closing the Loop

Most workflows are linear:

  1. Design
  2. Test
  3. Fix
  4. Repeat

This partnership compresses that loop.

New workflow:

  • In silico prediction (Kemp)
  • High-throughput validation (OneCyte)
  • Rapid optimization

Result: Faster iteration cycles with higher success probability.

Why This Matters for Modern Biologics?

Traditional systems were built for:

  • Monoclonal antibodies
  • Relatively stable molecules

But today’s pipeline includes:

  • Multi-specifics
  • Fusion proteins
  • Complex modalities

These are harder to express. Harder to scale. Harder to stabilize. This collaboration is built specifically for that future.

Hidden Advantage: No Licensing Constraints

The partnership includes access to:

  • CHO-K1 GS knockout cell line

Transposase-based expression system

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!